- Guys, Take the Lead in Self-Checks for Testicular Cancer
- Re-focusing on Getting Fit? Heart Experts Offer These Tips
- AHA News: Not Just Bad Shoes and Sore Muscles – She Had Peripheral Artery Disease
- Scientists Find Clues to Why AstraZeneca’s Vaccine May Cause Clots
- Stressed, Exhausted: Frontline Workers Faced Big Mental Strain in Pandemic
- Supply of J&J COVID Vaccine to Drop 86 Percent Next Week
- Health Highlights: April 9, 2021
- Nearly Half of U.S. Veterans Cited ‘Personal Growth’ During Pandemic: Survey
- Bright Side: Sunnier Areas Have Lower COVID-19 Death Rates
- Pandemic Has Put Many Clinical Trials on Hold
First Generic Version of Xeloda Approved
MONDAY, Sept. 16The first generic version of the oral chemotherapy drug Xeloda (capecitabine) has been approved by the U.S. Food and Drug Administration to treat cancers of the colon/rectum or breast, the agency said Monday in a news release.
This year, an estimated 142,820 people will be diagnosed with cancer of the colon/rectum, and 50,830 are predicted to die from the disease, the FDA said, citing the U.S. National Cancer Institute. An estimated 232,340 women will be diagnosed with cancer of the breast this year, and some 39,620 will die from it.
The most common side effects of the drug are diarrhea, vomiting; pain, redness, swelling or sores in the mouth; fever and infection, the FDA said.
The agency stressed that approved generics have the same high quality and strength as their brand-name counterparts.
License to produce the generic drug was given to Israel-based Teva Pharmaceuticals. The brand name drug is produced by the Swiss pharma firm Roche.
More information
Medline Plus has more about this drug.
Source: HealthDay
